- Home
- HE vs MESO Comparison
HE vs MESO Comparison
Compare HE & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HE | MESO |
|---|---|---|
| Founded | 1891 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 1994 | 2005 |
Fundamental Metrics
Financial Performance| Metric | HE | MESO |
|---|---|---|
| Price | $11.77 | $15.60 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $13.25 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 214.0K |
| Earning Date | 05-08-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 106.32 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $3,086,896,000.00 | N/A |
| Revenue This Year | $7.00 | $629.74 |
| Revenue Next Year | $4.06 | $30.65 |
| P/E Ratio | $13.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.79 | $12.66 |
| 52 Week High | $17.33 | $21.50 |
Technical Indicators
Market Signals| Indicator | HE | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 28.72 | 49.63 |
| Support Level | $11.03 | $15.35 |
| Resistance Level | $11.84 | $15.96 |
| Average True Range (ATR) | 0.31 | 0.35 |
| MACD | -0.11 | 0.10 |
| Stochastic Oscillator | 25.27 | 50.65 |
Price Performance
Historical ComparisonAbout HE Hawaiian Electric Industries Inc.
Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.